Table 1.
Parameter | Estimate | Data Source Used in Derivations | ||||
---|---|---|---|---|---|---|
Cohort Characteristics
| ||||||
Demographics | Mean (SD) or Percent | Lane et al. 201017 | ||||
Mean Age | 58.7 (7.9) | |||||
Percent Female | 59% | |||||
Percent White | 88% | |||||
Percent K-L 2 | 30% | |||||
Percent K-L 3 | 53% | |||||
WOMAC Pain | 67(13) | |||||
Starting WOMAC Pain | ||||||
15–40 | 41–70 | 71+ | ||||
|
||||||
Percent of Cohort | 2% | 58% | 41% | |||
| ||||||
Quality of Life Utilities (Nonobese/Obese) | WOMAC Pain (0–100) | Osteoarthritis Initiative38 | ||||
0 Comorbidities | Brazier et al. 200439 | |||||
|
||||||
Age Group | 0 | 1–15 | 16 – 40 | 41 – 70 | 71 – 100 | |
|
||||||
25–44 | 0.865/0.845 | 0.840/0.820 | 0.781/0.761 | 0.699/0.679 | 0.609/0.589 | |
45–54 | 0.841/0.830 | 0.816/0.806 | 0.780/0.769 | 0.714/0.703 | 0.656/0.645 | |
55–64 | 0.847/0.836 | 0.822/0.812 | 0.786/0.775 | 0.720/0.709 | 0.662/0.651 | |
65–74 | 0.871/0.860 | 0.846/0.835 | 0.810/0.799 | 0.744/0.733 | 0.685/0.675 | |
75+ | 0.854/0.843 | 0.829/0.818 | 0.793/0.782 | 0.727/0.716 | 0.669/0.658 | |
1 Comorbidity | ||||||
|
||||||
Age Group | 0 | 1–15 | 16 – 40 | 41 – 70 | 71 – 100 | |
|
||||||
25–44 | 0.845/0.825 | 0.820/0.800 | 0.761/0.741 | 0.679/0.659 | 0.589/0.569 | |
45–54 | 0.818/0.807 | 0.791/0.780 | 0.755/0.744 | 0.679/0.668 | 0.645/0.634 | |
55–64 | 0.824/0.813 | 0.797/0.786 | 0.761/0.750 | 0.685/0.674 | 0.651/0.640 | |
65–74 | 0.848/0.837 | 0.821/0.810 | 0.785/0.774 | 0.708/0.698 | 0.674/0.664 | |
75+ | 0.831/0.820 | 0.804/0.793 | 0.768/0.757 | 0.692/0.681 | 0.658/0.647 | |
2+ Comorbidities | ||||||
|
||||||
Age Group | 0 | 1–15 | 16 – 40 | 41 – 70 | 71 – 100 | |
|
||||||
25–44 | 0.825/0.805 | 0.800/0.780 | 0.741/0.721 | 0.659/0.639 | 0.569/0.549 | |
45–54 | 0.806/0.795 | 0.794/0.783 | 0.732/0.721 | 0.635/0.624 | 0.500/0.489 | |
55–64 | 0.812/0.801 | 0.800/0.789 | 0.738/0.727 | 0.641/0.630 | 0.506/0.495 | |
65–74 | 0.836/0.825 | 0.824/0.813 | 0.762/0.751 | 0.665/0.654 | 0.530/0.519 | |
75+ | 0.819/0.808 | 0.807/0.796 | 0.745/0.734 | 0.648/0.637 | 0.513/0.502 | |
| ||||||
Underlying Medical Costs | Comorbidities | Pope et al 201441 NHANES 2009–201233 MCBS 200943 Red Book Online53 CPI63 |
||||
Age group | 0–1 | 2–3 | 4+ | |||
|
||||||
25–34 | $1,400 | $7,500 | $14,300 | |||
35–44 | $2,000 | $8,000 | $14,300 | |||
45–49 | $2,700 | $8,200 | $14,300 | |||
50–54 | $2,700 | $8,200 | $14,300 | |||
55–59 | $3,500 | $8,800 | $14,700 | |||
60–64 | $4,300 | $9,600 | $15,500 | |||
65–69 | $4,600 | $9,900 | $15,500 | |||
70–74 | $5,300 | $10,700 | $16,200 | |||
75–79 | $6,200 | $11,600 | $17,100 | |||
80+ | $8,200 | $13,500 | $19,100 | |||
| ||||||
Tanezumab Treatment Characteristics
| ||||||
Annual Cost (2014 USD) | Drug Cost | Administrative Cost | Monitoring Cost | |||
First Year | 200, 400, 600, 800, 1000 | 61, 69, 133, 241, 433 | 277, 495 | |||
Subsequent Years | 200, 400, 600, 800, 1000 | 0, 69, 133, 241, 433 | 277, 495 | Medicare Fee Schedules49 | ||
| ||||||
Pain Relief | Starting Pain | |||||
|
||||||
15–40 | 41–70 | 71+ | ||||
|
||||||
Mean (SD) Pain Reduction | 13 (16) | 29 (18) | 41 (18) | Lane et al 201017 | ||
Late Failure Rate (%) | 10 | - | - | Klareskog et al. 200645 | ||
Max Years Efficacy | 15 | - | - | Assumption | ||
| ||||||
Adverse Effects | Minor Toxicity | Major Toxicity | ||||
First Year Rate (%) | 60 | 1 | Hochberg et al. 201548 | |||
Subsequent Years Rate (%) | 30 | 0.5 | ||||
QOL Multiplier | 0.997 | 0.59 | ||||
Cost (2014 USD) | 52 | 137 |
In 2014 USD. Values exclude as needed pain management. An annual cost of $102 was added for patients with symptomatic knee OA
Minor toxicity disutility and cost based on NSAID toxicity characteristics. Rate of minor toxicity was assumed. Major toxicity cost based on additional physician office visits and x-rays to diagnose rapid OA progression. Major toxicity disutility calibrated to yield QOL of 0.5 immediately prior to TKR following rapid OA progression.